177 related articles for article (PubMed ID: 1293910)
1. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
Hansz J; Włodarczyk M; Psuja P
Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
[TBL] [Abstract][Full Text] [Related]
2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
4. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
[TBL] [Abstract][Full Text] [Related]
5. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
6. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
Segeren CM; Sonneveld P; van der Holt B; Baars JW; Biesma DH; Cornellissen JJ; Croockewit AJ; Dekker AW; Fibbe WE; Löwenberg B; van Marwijk Kooy M; van Oers MH; Richel DJ; Schouten HC; Vellenga E; Verhoef GE; Wijermans PW; Wittebol S; Lokhorst HM
Br J Haematol; 1999 Apr; 105(1):127-30. PubMed ID: 10233375
[TBL] [Abstract][Full Text] [Related]
7. [VAD chemotherapy of multiple myeloma].
Amano M; Itoh K; Togawa A
Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
[TBL] [Abstract][Full Text] [Related]
9. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
10. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
13. [Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone].
Egerer G; Hegenbart U; Salwender H; Hahn U; Haas R; Goldschmidt H; Hunstein W
Dtsch Med Wochenschr; 1997 Apr; 122(17):531-5. PubMed ID: 9190299
[TBL] [Abstract][Full Text] [Related]
14. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
15. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
16. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
17. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
Jimenez-Zepeda VH; Domínguez-Martínez VJ
Eur J Haematol; 2006 Sep; 77(3):239-44. PubMed ID: 16856924
[TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
[TBL] [Abstract][Full Text] [Related]
19. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
Teng HW; Teng CJ; Wang WS; Chen PM; Chiou TJ; Hsu HC; Liu JH; Yen CC; Hsiao LT; Yang MH; Chao TC; Yang YH; Gau JP
Am J Hematol; 2010 Oct; 85(10):812-5. PubMed ID: 20734459
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.
Cesana C; Nosari AM; Klersy C; Miqueleiz S; Rossi V; Ferrando P; Valentini M; Barbarano L; Morra E
Haematologica; 2003 Sep; 88(9):1022-8. PubMed ID: 12969810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
